Literature DB >> 19022194

Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme.

Heikki Peltola1, Sari Jokinen, Mikko Paunio, Tapani Hovi, Irja Davidkin.   

Abstract

A nationwide programme to eliminate indigenous measles, mumps, and rubella, mainly by vaccinating children twice, was launched in Finland in 1982. Strong scientific methods to examine the immunological, clinical, and epidemiological variables have accompanied the programme. Measles was eliminated in 1996, and mumps and rubella in 1997. Now, 25 years from the start of this programme, Finland is facing new challenges. Since elimination, eight, 32, and six cases of measles, mumps, and rubella, respectively, have been reported. Of those, seven cases were failures of mumps vaccinations and one case was a rubella vaccination failure. Although outbreaks have been averted, the risks are increasing because the unvaccinated population is growing, epidemics occur in nearby countries, breakthrough cases arise, and declining antibodies suggest waning immunity. The chances for natural boosters are now at a minimum, and individuals are increasingly protected solely by vaccination. To maintain the absence of these diseases, the adopted policy should continue, but the country should also be prepared for prompt supplementary vaccinations in the case of epidemic outbreaks.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022194     DOI: 10.1016/S1473-3099(08)70282-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  12 in total

1.  Seropositivity rates for measles, mumps, and rubella IgG and costs associated with testing and revaccination.

Authors:  Brian H Shirts; Ryan J Welch; Marc Roger Couturier
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

2.  The influence of social norms on the dynamics of vaccinating behaviour for paediatric infectious diseases.

Authors:  Tamer Oraby; Vivek Thampi; Chris T Bauch
Journal:  Proc Biol Sci       Date:  2014-02-12       Impact factor: 5.349

Review 3.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

4.  Measles: an adult case during a local outbreak.

Authors:  Aaron Gabriel Sutherland; Kate Barnabas; Kemparaju Haribhaskar
Journal:  BMJ Case Rep       Date:  2009-06-26

5.  Close the gap for routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

Review 6.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

7.  Viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain.

Authors:  Irene Barrabeig; Josep Costa; Ariadna Rovira; M Angeles Marcos; Ricard Isanta; Rubén López-Adalid; Ana Cervilla; Nuria Torner; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 8.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

9.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

10.  Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital.

Authors:  Taito Kitano; Masayuki Onaka; Mariko Ishihara; Atsuko Nishiyama; Naoki Hashimoto; Sayaka Yoshida
Journal:  Clin Exp Vaccine Res       Date:  2017-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.